<DOC>
	<DOCNO>NCT01483300</DOCNO>
	<brief_summary>Gemcitabine plus cisplatin prove effective regimen second-line treatment metastatic breast cancer patient , especially previously treat anthracyclines taxanes . Lobaplatin , third generation new cancer drug platinum , similar anticancer activity cisplatin , less kidney toxicity gastrointestinal reaction . The purpose study compare efficacy safety gemcitabine/lobaplatin versus gemcitabine/cisplatin patient metastatic breast cancer .</brief_summary>
	<brief_title>Effectiveness Toxicity Gemcitabine/Lobaplatin Versus Gemcitabine/Cisplatin Second-line Treatment Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically confirm metastatic breast cancer Disease progression previous 1st line chemotherapy Scheduled receive 2nd line chemotherapy . Measurable disease , define least one lesion accurately measure least one dimension 18 year age old ECOG performance status 02 Life expectancy great 6 month Previous treatment one study drug Application cytotoxic chemotherapy radiotherapy Insufficent renal function ( creatinine clearance &lt; 60ml/min ) Clinically unstable brain metastasis Pregancy lactation History malignancy within last 5 year .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>lobaplatin</keyword>
	<keyword>cisplatin</keyword>
</DOC>